2024
Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients
Ringer M, Malinis M, McManus D, Davis M, Shah S, Trubin P, Topal J, Azar M. Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients. Transplant Infectious Disease 2024, 26: e14249. PMID: 38319665, DOI: 10.1111/tid.14249.Peer-Reviewed Original ResearchLength of stayIntensive care unitBaloxavir groupClinical outcomesSecondary outcomesIntensive care unit length of stayRetrospective study of hospitalized patientsEfficacy of baloxavirResolution of feverImmunocompromised adult patientsStudy of hospitalized patientsRetrospective cohort studyAssociated with longer timeResolution of hypoxiaOseltamivir groupInfluenza subtypesImmunocompromised patientsInfluenza ANo significant differenceMedian timeResistance ratesNeuraminidase inhibitorsRetrospective studyBaseline characteristicsAdult patients
2022
The cascade of care in testing and treatment of latent tuberculosis infection in liver transplant candidates
Palacios C, Medvedeva N, Cheung H, Cohen E, Azar M, Malinis M. The cascade of care in testing and treatment of latent tuberculosis infection in liver transplant candidates. Transplant Infectious Disease 2022, 25: e13999. PMID: 36484433, DOI: 10.1111/tid.13999.Peer-Reviewed Original ResearchConceptsLatent tuberculosis infectionLT candidatesIndeterminate IGRALTBI testingTuberculosis infectionCascade of carePost-liver transplantLiver transplant candidatesProportion of patientsRetrospective chart reviewTB-endemic countriesInterferon-gamma releaseTreatment completion ratesCompletion ratesLTBI treatmentPositive IGRATB reactivationCare cascadeTreatment-naïveChart reviewSecondary outcomesTransplant candidatesPrimary outcomeTreatment initiationChest imaging
2018
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppression